Ophthalmology. Glaucoma · 2025
Influence of CYP1B1 Variants on Phenotypic Characteristics and Therapeutic Outcomes in Primary Congenital Glaucoma.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rodrigues Rita, Alves David, Esteves-Leandro João, Silva Marta, Barbosa-Breda João, Tavares-Ferreira João, Araújo Joana, Fernandes Susana, Oliveira Renata, Melo António, Alves Flávio, Magalhães Augusto, Cotta José, Estrela-Silva Sérgio
Аннотация
PURPOSE: To identify CYP1B1 variants in primary congenital glaucoma (PCG) patients from Northern Portugal and examine genotype-phenotype correlations.
DESIGN: Cross sectional observational study.
PARTICIPANTS: Seventy-one patients diagnosed and treated for PCG at ULS São João, Porto, Portugal, were included. These patients met the following criteria: available genetic testing data, a minimum follow-up period of 1 year, and the last appointment between January 2022 and January 2024.
METHODS: Demographic and clinical data were collected. CYP1B1 variants were screened using DNA sequencing. A next-generation sequencing (NGS) glaucoma panel was performed in patients with heterozygous or absent CYP1B1 variants in the screening. Genotype-phenotype correlations were assessed by comparing clinical characteristics between patients with identified biallelic plausible disease-causing variants in CYP1B1 variants and those with negative genetic testing results.
MAIN OUTCOME MEASURES: CYP1B1 variants, sex, laterality, age at diagnosis, age at first surgery, number of surgical procedures, number of intraocular pressure (IOP)-lowering medications, IOP at last follow-up, and final best-corrected visual acuity (BCVA).
RESULTS: Sixty-six unrelated probands and 5 affected relatives (133 eyes) were analyzed. Two plausible disease-causing CYP1B1 variants were identified in 60.6% (43/71) of patients. Nineteen distinct CYP1B1 variants were identified, including 4 novel variants. The most frequent variants were c.535del (43.5%) and c.1200_1209dup (28.2%). Compared with negative genetic testing group (n = 22), patients with CYP1B1 variants (n = 43) showed significantly higher rates of bilateral disease (100% vs. 68%, P < 0.001), earlier disease onset (median 0 vs. 5.5 months, P < 0.001), poorer final BCVA (median 0.5 vs. 0.25 logarithm of the minimum angle of resolution, P = 0.025), higher IOP at last follow-up (median 16 vs. 12 mmHg, P < 0.001), and greater need for surgical interventions (median 2 vs. 1, P = 0.014) and IOP-lowering medications (median 2 vs. 0, P = 0.005). Next-generation sequencing testing in CYP1B1-negative patients identified 3 novel heterozygous variants of uncertain significance in the TEK gene.
CONCLUSIONS: Primary congenital glaucoma patients from Northern Portugal with CYP1B1 variants are more likely to present with bilateral disease, earlier onset, and a more severe clinical phenotype, suggesting a strong genotype-phenotype correlation.
FINANCIAL DISCLOSURE(S): The authors have no proprietary or commercial interest in any materials discussed in this article.
DESIGN: Cross sectional observational study.
PARTICIPANTS: Seventy-one patients diagnosed and treated for PCG at ULS São João, Porto, Portugal, were included. These patients met the following criteria: available genetic testing data, a minimum follow-up period of 1 year, and the last appointment between January 2022 and January 2024.
METHODS: Demographic and clinical data were collected. CYP1B1 variants were screened using DNA sequencing. A next-generation sequencing (NGS) glaucoma panel was performed in patients with heterozygous or absent CYP1B1 variants in the screening. Genotype-phenotype correlations were assessed by comparing clinical characteristics between patients with identified biallelic plausible disease-causing variants in CYP1B1 variants and those with negative genetic testing results.
MAIN OUTCOME MEASURES: CYP1B1 variants, sex, laterality, age at diagnosis, age at first surgery, number of surgical procedures, number of intraocular pressure (IOP)-lowering medications, IOP at last follow-up, and final best-corrected visual acuity (BCVA).
RESULTS: Sixty-six unrelated probands and 5 affected relatives (133 eyes) were analyzed. Two plausible disease-causing CYP1B1 variants were identified in 60.6% (43/71) of patients. Nineteen distinct CYP1B1 variants were identified, including 4 novel variants. The most frequent variants were c.535del (43.5%) and c.1200_1209dup (28.2%). Compared with negative genetic testing group (n = 22), patients with CYP1B1 variants (n = 43) showed significantly higher rates of bilateral disease (100% vs. 68%, P < 0.001), earlier disease onset (median 0 vs. 5.5 months, P < 0.001), poorer final BCVA (median 0.5 vs. 0.25 logarithm of the minimum angle of resolution, P = 0.025), higher IOP at last follow-up (median 16 vs. 12 mmHg, P < 0.001), and greater need for surgical interventions (median 2 vs. 1, P = 0.014) and IOP-lowering medications (median 2 vs. 0, P = 0.005). Next-generation sequencing testing in CYP1B1-negative patients identified 3 novel heterozygous variants of uncertain significance in the TEK gene.
CONCLUSIONS: Primary congenital glaucoma patients from Northern Portugal with CYP1B1 variants are more likely to present with bilateral disease, earlier onset, and a more severe clinical phenotype, suggesting a strong genotype-phenotype correlation.
FINANCIAL DISCLOSURE(S): The authors have no proprietary or commercial interest in any materials discussed in this article.